Question to the Department of Health and Social Care:

To ask His Majesty's Government whether (1) the Department of Health and Social Care, (2) its agencies, and (3) NHS England, hold information about individual GPs who are prescribing hormone treatments and other drugs, such as spiralactone and gonadotropin-releasing hormone agonists, to transgender individuals who are (a) older than 18 years old, and (b) younger than 18 years old.

The Department does not hold this information. NHS England does hold this information on an exceptional basis when concerns are made about the prescribing practices of individual general practices, including when the concerns have been made as part of a professional standards investigation.

For patients who are under 18 years old, the NHS stopped the routine prescription of puberty blocker treatments to under 18s in March 2024, following the findings of the Cass Review into gender services. Gonadotropin-releasing hormone (GnRH) analogues were subsequently restricted as part of an emergency banning order which took effect June 2024.

In August 2024, NHS England wrote to all general practitioners (GPs) in England responsible for prescribing GnRH analogues, to clarify application of this new legislation in clinical practice-based scenarios. In December 2024, the Department announced that the order banning the use of puberty blockers for individuals younger than 18 years old would be made indefinite. A further update to NHS England’s guidance was provided to GPs that same month.

In May 2025, NHS England issued guidance that advised GPs not to support unregulated providers in prescribing hormone treatments for gender incongruence to children and young people under 18 years old.